Drug updated on 9/4/2024
| Dosage Form | Solution (topical ophthalmic; 0.02 mg/mL (0.002%)) |
| Drug Class | Relatively selective prostaglandin E2 (EP2) receptor agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Latest News
Summary
- Omlonti (omidenepag isopropyl) is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Omidenepag Isopropyl (OMDI) monotherapy led to a significant reduction in intraocular pressure (IOP) with a weighted mean difference of -4.684 (95% CI: -6.010 to -3.358) among 358 eyes across six studies, indicating its effectiveness in lowering IOP in glaucoma patients.
- Subgroup analyses indicated that patients with initial IOP >21 mmHg and those older than 65 years experienced significant reductions in IOP post-OMDI treatment.
- The meta-analysis revealed a high level of heterogeneity (I² = 91.092%) among the included studies, suggesting variability in the study outcomes.
- There is no safety information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Omlonti (omidenepag isopropyl ophthalmic solution) Prescribing Information. | 2022 | Santen Incorporated, Emeryville, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinical efficacy of omidenepag isopropyl for primary open-angle glaucoma, normal tension glaucoma, or ocular hypertension: A meta-analysis. | 2023 | Journal Of Ocular Pharmacology and Therapeutics |